After a median follow-up of 6 years, an intent-to-treat analysis showed a median survival of 4.48 vs 1.79 years in favour of trimodality therapy (exact stratified log-rank, p=0.002). 5 year survival was 39% (95% CI, 21% to 57%) vs 16% (95% CI, 5% to 33%) in favour of trimodality therapy.r
Kaplan-Meier estimates of overall survival (OS)r
Kaplan-Meier estimates of overall survival (OS) by treatment arm measured from study entry until death from any cause. (*) NE, not estimable. † Asymptotic results for OS were comparable to to those obtained using the exact method.
© Journal of Clinical Oncology 2008
The survival benefit from neoadjuvant chemotherapy or chemoradiotherapy over surgery alone was also confirmed by a meta-analysis by Sjoquist et al. The HR for all-cause mortality for neoadjuvant chemoradiotherapy was 0.78 (95% CI 0.70 to 0.88; p<0.0001); the HR for squamous-cell carcinoma only was 0.80 (95% CI 0.68-0.93) and for adenocarcinoma only was 0.75 (95% CI 0.59-0.95).r